Mitsubishi Tanabe Pharma America Inc (MTPA), a subsidiary of Japan-based Mitsubishi Tanabe Pharma Corporation (MTPC), announced on Monday that it has changed its corporate name to Tanabe Pharma America Inc (TPA), effective immediately.
In July, MTPC said that it would change name to Tanabe Pharma Corporation, effective 1 December 2025, following its acquisition by private investment firm Bain Capital.
TPA will continue to pursue a robust pipeline of products for hard-to-treat diseases, including neurodegenerative diseases, inflammatory, and metabolic conditions, the company said.
LEO Pharma advances delgocitinib cream into phase 3 trial for lichen sclerosus
HistoIndex partners Houston Research Institute
Formosa Pharmaceuticals licenses APP13007 ophthalmic therapy to Samil for South Korea
Bambusa Therapeutics reports first patient dosed in proof-of-concept COPD trial
Elanco Animal Health's Befrena (tirnovetmab) receives USDA approval for canine dermatitis
Sanofi and Regeneron's Dupixent gains Japan approval for paediatric asthma patients aged 6 to 11
Aqualung Therapeutics' Phase 2a lung fibrosis study approved by US FDA
Alvotech launches first-in-market golimumab biosimilar in Europe
Physiomics secures follow-on UK contract for Phase 2 study support
RedHill Biopharma reports positive opaganib data in venetoclax-resistant CLL
InduPro secures strategic investment and collaboration with Sanofi to advance autoimmune therapy
Innovent Biologics reports first participant dosed in Phase 1 trial of IBI3011